Gland Pharma reported that integrated net profit increased by about 50% for the June quarter to ₹ 143.8 crore to ₹ 215.5 crore, as all major American markets increased.
High net profit operations came up to Rs 1,505.6 crore (.7 1,401.7 crore) at more than 7% increase in revenue. Market wise performance numbers showed that the revenue of the generic injected-centered company from Hyderabad to Hyderabad fell 2% to 2% 744.3 crore (.8 762.8 crore).
The sales of Canada, Australia and New Zealand (other main markets) increased by 65% to 65% (73.9 crore (₹ 44.7 crore), while revenue from Europe increased 29% ₹ 330.2 crore (₹ 256.6 crore). In India, sales increased by 13% to ₹ 59.4 crore (₹ 52.7 crore). Revenue increased by 5% from the rest of the world market. (.9 284.9 crore).
A strong performance in the company’s Aadhaar business and a turnaround in senex, the French firm that was achieved a few years ago, was behind the revenue growth and jumped into profitability, said the executive chairman Srinivas Sadu.
“These results show that our strategic priorities are progressing. We are strengthening our abilities, adding new abilities and increasing research and development with complex products and major partnerships,” he said in a release.
CEO Shyamakant Giri said, “To increase our Aadhaar business, to invest in differentiated products and run operating capacity, we are giving ourselves a place for continuous development.”
Published – August 05, 2025 10:14 pm IST
